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No standardized PCR method is available for the laboratory diagnosis of the pertussis syndrome. Consensus
recommendations for the use of PCR in the diagnosis of Bordetella pertussis infections have been proposed, and
the aim of this study was to develop a method that fulfills all of these criteria. A rapid-cycle shared-primer PCR
method with a microwell format and probe hybridization detection step (POR) was developed using novel
oligonucleotides targeted to the outer membrane porin gene (Bordetella spp.). In specimens positive for
Bordetella spp., B. pertussis was differentiated from Bordetella parapertussis and Bordetella bronchiseptica by
hybridization with organism-specific oligonucleotide probes. An internal control was developed using overlap
extension PCR and mouse b-actin DNA. The analytical specificity was 100%. The analytical sensitivity was
comparable to that of nested IS481 and IS1001 PCR (;1 organism per reaction). The clinical sensitivity and
specificity were ascertained using 705 specimens (from 705 patients). The results were compared to those of a
nested-PCR method targeting the insertion sequences IS481 and IS1001. Fifty-one specimens were positive for
B. pertussis by POR and IS481 PCR. Two specimens which fulfilled a clinical definition of pertussis were
positive by POR and negative by IS481 PCR. A total of 652 specimens were negative by both methods. B.
parapertussis was not detected in any specimens. PCR inhibition was detected in 21 out of 705 specimens
(2.98%). Thus, a rapid (4 h, including specimen preparation) PCR method which fulfills all of the consensus
recommendations was developed and validated for the detection of B. pertussis.
The diagnosis of Bordetella pertussis infections by nucleic
acid amplification-based methods has, in general, been shown
to be both highly sensitive and specific (13), yet an agreed-
upon standardized method has not yet been adopted. The
following consensus international recommendations have been
published (11). (i) Sample processing should be kept to a
minimum. (ii) Nasopharyngeal aspirates (NPA) are the pre-
ferred specimens. (iii) Differentiation between B. pertussis and
Bordetella parapertussis is necessary. (iv) Carryover control
(e.g., uracil-N-glycosylase) should be used to minimize contam-
ination. (v) Appropriate controls (positive and negative) should
be used. (vi) In detection systems, probes should be used for
added specificity and sensitivity. (vii) Confirmation of ques-
tionable results with an alternative target is necessary. (viii)
One hundred percent of culture-positive results should be nu-
cleic acid amplification positive. (ix) Other commensals and
pathogens should test negative. (x) Testing of samples from a
healthy population assumed to be negative for the pathogen is
required. (xi) Use of an internal control to check for inhibition
of the reaction is required. However, as yet no method has
been offered which fulfills all of these criteria. In a previous
study (1), we developed a nested-PCR method utilizing the
insertion sequences IS481 (B. pertussis) and IS1001 (B. para-
pertussis). Although the method had high analytical and clinical
sensitivity and specificity and differentiated between B. pertus-
sis and B. parapertussis, it was not useful for the routine diag-
nostic laboratory. Our efforts since then have been directed at
developing a simpler method. In this study, we describe a
rapid-cycle method which fulfills all of the consensus interna-
tional recommendations and evaluate it using nested PCR
utilizing both prospective specimens and specimens from a
previous study (1). The results show that this method would be
highly suited to serve as a standardized B. pertussis PCR
method.
MATERIALS AND METHODS
Bacterial strains and genomic DNA. The bacterial strains and genomic DNA
for sensitivity and specificity studies were the same as those described previously
(1). Additional strains tested were Bordetella avium strain TC9 and Bordetella
hinzii strain TC58, both kindly donated by Patrick Blackall from the Queensland
Department of Primary Industries Animal Research Institute, Brisbane, Austra-
lia, and four Bordetella holmesii strains.
Patient specimens. Specimen collection, initial treatment, and storage were as
previously described (1). A total of 705 specimens (from 705 patients) were
tested. The specimen types were as follows: NPA, 608; throat (posterior pharyn-
geal) swabs, 82; and sputum, 15. Six hundred fifteen specimens were from
patients with respiratory symptoms. Sixty-five NPA were from healthy asymp-
tomatic adults, initially thought to be contacts in a pertussis outbreak which was
later confirmed as an influenza A outbreak. Twenty-five throat swabs were
collected from healthy adult volunteers. Samples were removed from the freezer
(220°C) and thawed at 37°C for 30 min. Twenty microliters was added to 80 ml
of sterile DNase- and RNase-free water, vortexed for 30 s, heated in a dry block
heater for 20 min at 99.9°C, and then pulse centrifuged in a bench microcentri-
fuge (set at 11,300 3 g) for 30 s. Positive and negative controls were treated
identically to specimens. Specimens in which inhibitory substances were detected
(see the method described below) underwent a DNA extraction procedure using
the High Pure PCR template kit (Boehringer Mannheim, Sydney, Australia)
according to the manufacturer’s instructions prior to retesting.
PCR methods. Nested IS481 PCR was performed as previously described (1).
Pertussis toxin operon (PTO) PCR was also performed as described previously
(D. J. Farrell, M. McKeon, G. Daggard, and T. K. S. Mukkur, Abstr. 39th
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Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1569, p. 225, 1999). Oli-
gonucleotides for POR used in this study were designed (Fig. 1) using previously
published sequence data (5) and are listed in Table 1. They were synthesized
commercially by Life Technologies.
For the POR PCR, 10 ml of treated specimen was added to 40 ml of a master
mixture (made immediately before use) containing 5 ml of 103 PCR buffer; PCR
nucleotide mixture (Boehringer Mannheim) (200 mM dATP, dCTP, and dGTP;
600 mM dUTP); 12.5 pmol (each) of primers DFPOR1F, DFPOR2F, and
DFPORRB; 2.0 U of platinum Taq polymerase (Life Technologies) per reaction
mixture; 2.5 mM MgCl2 (Life Technologies); and titrated internal control. One
microliter of uracil-DNA glycosylase (heat labile) (Boehringer Mannheim) was
added to each master mixture and incubated at room temperature for 10 min
before amplification. Amplification was performed in a GeneAmp 9600 thermal
cycler (Perkin-Elmer Applied Biosystems, Melbourne, Australia) with the fol-
lowing parameters: 2 min at 95°C followed by 44 cycles of 10 s at 94°C, 10 s at
56°C, and 5 s at 72°C, with the last cycle concluding with a reaction for 5 min at
72°C.
Detection of amplified products was performed using a modification of the
PCR digoxigenin (DIG) enzyme-linked immunosorbent assay (ELISA) kit
(Boehringer Mannheim). The oligonucleotide probes DFPORP1, DFPORP2,
DFPORP3, and DFMBAP were labeled with DIG-ddUTP or -dATP using the
DIG oligonucleotide 39 end labeling kit (Boehringer Mannheim) according to
the manufacturer’s instructions. Unless specified, the reagents described in the
following methodology are those present in the PCR DIG ELISA kit. Twenty
microliters of denaturation solution (reagent 1a) was added to each streptavidin-
coated microwell. Five microliters of each amplified specimen was added to each
of two wells. The contents of the microwell plate were gently mixed and allowed
to sit at room temperature for 10 min. During this time, probes were prepared
for addition to the microwells. DIG-labeled probes (DFPORP3 for Bordetella
spp. and DFMBAP for the internal control) were diluted 1/200 in hybridization
buffer (reagent 2) and gently mixed by inversion. Two hundred microliters of
diluted probe was added to the appropriate microwells, and the plate was cov-
ered with a plastic plate cover and incubated at 45°C on a heating block for 30
min. During hybridization, the conjugate was prepared by diluting the anti-DIG-
peroxidase 1/100 with conjugate dilution buffer (reagent 4). At 30 min, the plate
was washed six times on an automated enzyme immunoassay plate washer (Sorin;
CSL Biosciences, Melbourne, Australia) using PCR ELISA buffer. One hundred
microliters of the prepared conjugate was added to each well, and the plate was
covered and incubated at 37°C for 30 min in a plate incubator (Sanofi Diagnos-
tics, Sydney, Australia). The plate was then washed six times. One hundred
microliters of freshly combined TMB substrate (Roche Diagnostics, Sydney,
Australia) was added to each well. The reaction was stopped exactly 5 min after
the addition of the substrate by adding 100 ml of 10% H2SO4.
A cutoff for the positive result was obtained from the mean of five readings
(from five separate runs) of a specimen diluted to approximately one viable
CFU/reaction mixture, and an equivocal result was determined from a similar
series using 1/5 to 1/2 dilutions of the positive cutoff specimen. A specimen was
considered negative for Bordetella spp. if the absorbance measured at 450 nm
with a reference measurement at 620 nm (A450/620) was #0.2, positive if the
A450/620 was $0.8, and equivocal if the A450/620 was .0.2 and ,0.8. Any run in
which a negative control was positive or a positive control was negative was
repeated. Any specimen in which the internal control value was ,0.5 was con-
sidered to have PCR inhibition, and a DNA purification step was performed
using the High Pure PCR template kit before the test was repeated.
If a positive signal for Bordetella spp. was obtained, the hybridization step was
repeated using the probes DFPORP1 (for B. pertussis) and DFPORP2 (for B.
parapertussis and B. bronchiseptica).
In Iowa, to check that B. holmesii did not cross-react with the assay, the
method was performed with four strains of B. holmesii with appropriate positive
and negative controls. No testing of clinical isolates described in this study was
performed. Modifications of the method described above were as follows. POR
PCR was performed using biotinylated primers. Amplified products were de-
tected and interpreted as previously described (7), using a colorimetric microwell
assay in which unlabeled POR capture probes were immobilized in plate wells.
Wells that contained hybridized PCR product generated color after the addition
of avidin horseradish peroxidase and tetramethylbenzidine substrate. Following
FIG. 1. Primers and probes used for the PCR assay. The nucleotide sequence, located upstream from the outer membrane porin gene (obtained from reference
5), shows a 39 homogenous region between B. pertussis (Pert) and B. parapertussis (Para) and a 59 variable region. Primers and probes are underlined. The sequence
for the primer DFPORRB is the reverse complement of the underlined region. Sequence in italics shows Para sequence that differs from Pert sequence.
TABLE 1. Oligonucleotides used in this study to detect B. pertussis and B. parapertussis
Oligonucleotide Sequence
DFPOR1F........................................................................................................59GGCTCCTTGACTGAACTGG39
DFPOR2F........................................................................................................59TGAGGTCGGGCGAATCGTC39
DFPORRB.......................................................................................................59Biotin-GGTAAGTTGCAACATCCTGTC39
DFPORP1 ........................................................................................................59GAACCATGCATACAACCTATT39
DFPORP2 ........................................................................................................59GAGCTTGTTGCATTGCGATGC39
DFPORP3 ........................................................................................................59CGCGCGCGATTCCGGATTAAG39
DFPORFMB ...................................................................................................59GGCTCCTTGACTGAACTGGCTGTGGCATCCATGAAAC39
DFPORRMB...................................................................................................59GGTAAGTTGCAACATCCTGTCGCATAGAGGTCTTTACGGA39
DFMBAP .........................................................................................................59TCAATTCCATCATGAAGTGTGACGTTGA39
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washing and color development steps, the plates were read in a microwell plate
reader at A450.
Construction of an assay-specific internal control. In this study, mouse cDNA
was prepared from BALB/c mouse spleens used for a different study. Mouse
cDNA was used, as it was available; however, a simple DNA extract of mouse
DNA would suffice. Hybrid primers (DFPORFMB and DFPORRMB) were
designed using the sequence for mouse b-actin (GenBank accession no.
X03672); the nucleotide sequences are listed in Table 1. A master mixture was
prepared which had the following final concentrations: 13 PCR buffer (Life
Technologies); 200 mM (each) dATP, dCTP, dTTP, and dGTP (Pharmacia
Biotech); 10 pmol of specific oligonucleotide per reaction mixture; platinum Taq,
2.0 U/reaction mixture; and 1.5 mM MgCl2. Two microliters of mouse cDNA was
added to 47.5 ml of master mixture, and amplification was performed on a
GeneAmp 9600 thermal cycler using the following parameters: 94°C for 2 min;
29 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for 1 min; and 72°C for 5 min.
Products were visualized on a 2% Tris-borate-EDTA agarose gel using ethidium
bromide.
The resulting amplicon was of the same size as the amplicon for the B. pertussis
assay and had the same sequences at either end but contained mouse DNA in the
internal region. The internal control was then amplified by the diagnostic PCR
method to produce a large amount of internal control. The internal control was
then serially diluted and amplified in the standard B. pertussis assay, and the
cutoff for positivity was determined. One dilution higher than the cutoff concen-
tration was the concentration used in the master mixture. If PCR-inhibitory
substances were present in the specimen, they would be detected by failure to
amplify the internal control, which was detected in a separate microwell using an
oligonucleotide probe (DFMBAP) specific for mouse b-actin DNA.
RESULTS
Analytical specificity was 100% using the strains previously
described (1), B. avium strain TC9, B. hinzii strain TC58, and
four B. holmesii strains (Table 2). No positive results were
obtained for 65 NPA or 25 throat swabs collected from 90
asymptomatic healthy adults. The analytical sensitivity of the
assay was between 1 and 10 CFU per reaction mixture. Table
3 shows that analytical sensitivity was not adversely affected for
B. pertussis or B. parapertussis if either organism was present in
minimal numbers and the other in large numbers.
In the comparison between POR and IS481 nested PCR for
705 clinical specimens, 51 specimens were positive and 652
specimens were negative for both tests. No tests were positive
for IS481 and negative for POR; however, two POR-positive
and IS481-negative specimens were obtained. The two speci-
mens that produced discrepant results came from two patients
who fulfilled a clinical definition of pertussis (14) and were also
positive by PTO PCR. PCR inhibition was detected in 21 of
705 specimens (2.98%). Inhibitors were detected more fre-
quently in extremely mucoid specimens, of which 8 were spu-
tum and 13 were NPA. After DNA extraction, no inhibitors
were detected for any of the 21 specimens. One of the inhib-
itory specimens was positive for B. pertussis after DNA extrac-
tion.
DISCUSSION
Disadvantages of the nested IS481-IS1001 method arise
from the inherent problems of nested-PCR assays, in particu-
lar, the increased risk of carryover of amplified DNA. In ad-
dition, the carryover cannot be minimized by the use of the
uracil-N-glycosylase carryover prevention system. Because of
these problems, this method should only be performed in lab-
oratories with staff experienced in nested-PCR techniques, and
hence it is not suitable for routine laboratory use. The next step
was to develop a simpler assay, using the IS481-IS1001 assay as
a “gold standard” to evaluate the analytical and clinical pa-
rameters.
The two main candidates considered as appropriate targets
were the repetitive insertion sequence IS481 and the regula-
tory region of the pertussis toxin gene. IS481 is present in all
strains of B. pertussis tested so far at a rate of 50 to 100 copies
per chromosome (1, 9, 10). IS481 would seem like an appro-
priate target due to its high copy number, yet many have
questioned its use. Grimprel et al. (3) argued that the copy
number might vary between strains and that insertion se-
quences may also be present in other Bordetella species. To
assess the specificity of the insertion sequence, Glare et al. (2)
performed hybridization studies with 45 different species of
bacteria (from 24 genera) using a ClaI fragment as a probe.
Strong hybridization occurred for B. pertussis, weak hybridiza-
tion was observed for B. bronchiseptica (after prolonged auto-
radiography), and no hybridization was observed for any other
species. In all studies except that of Glare et al. (2), the spec-
ificity of IS481-based PCR has been 100% when tested against
a multitude of non-pertussis bordetellae, and a high correla-
tion has been observed with clinical pertussis and culture. On
the other hand, Glare et al. (2) reported a 12-bp difference
compared to the sequence published by McLafferty et al. (9),
suggesting that the insertion sequence is not absolutely con-
served. Also, a recent study (8) showed that an IS481 PCR
cross-reacted strongly with six strains of B. holmesii. Unfortu-
nately, the carriage rate and clinical significance of B. holmesii
are unknown, confounding assays that target IS481.
In the first attempt to develop a simpler assay, the pertussis
toxin operon was used as a target, and the PTO assay per-
formed well, both analytically and clinically, against nested
IS481-IS1001 (Farrell et al., Abstr. 39th Intersci. Conf. Anti-
microb. Agents Chemother.). Although ptx is present as a
single-copy gene, a comparison of PTO and IS481 as targets
showed equivalent sensitivities (4). On the other hand, identi-
cal PCR protocols were used for both IS481 and PTO, yet the
TABLE 3. Absorbances for reactions containing different amounts
of B. pertussis (strain Tohama I) and B. parapertussis
(strain ATCC 15237)
No. of bacteriaa A450/620b
B. pertussis B. parapertussis DFPOR1 DFPOR2 DFPOR3
1 107 0.03 2.2 2.25
10 107 1.2 2.3 2.1
100 105 2.25 2.35 2.4
103 103 2.3 2.15 2.25
105 100 2.15 1.95 2.1
107 10 2.4 1.6 2.35
107 1 2.25 0.25 2.05
a CFU per reaction mixture.
b Average of three readings.
TABLE 2. Specificities of the individual probes in the
POR assay for Bordetella spp.
Species
No. of strains positive for probe (target species)
DFPORP1
(B. pertussis)
DFPORP2
(B. parapertussis,
B. bronchiseptica)
DFPORP3
(B. pertussis,
B. parapertussis,
B. bronchiseptica)
B. pertussis (21)a 21 0 21
B. parapertussis (6) 0 6 6
B. bronchiseptica (3) 0 3 3
B. avium (2) 0 0 0
B. hinzii (2) 0 0 0
B. holmesii (4)b 0 0 0
Non-Bordetella (30)
(from reference 1)
0 0 0
a Number of individual strains tested is given in parentheses.
b Tested by the modified POR method in the Iowa laboratory.
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published melting temperatures (Tm) of the primers differed by
14 and 16°C between the two methods (4). One could argue
that with better optimization the IS481 PCR might have been
a great deal more sensitive than PTO PCR. There are argu-
ments for not using PTO as a target. (i) The pertussis toxin
gene is also present but not expressed in B. parapertussis and B.
bronchiseptica due to multiple mutations located in the ptx
promoter region (6). On the other hand, an immunoglobulin G
response to pertussis toxin in patients with parapertussis infec-
tions has been described, indicating that expression of the toxin
genes may occur (5). (ii) Mutations in the pertussis toxin S1
subunit have recently been described; Mooi et al. (12) provide
evidence that contemporary strains of B. pertussis differ in the
genetic sequence of the S1 subunit, possibly through vaccine-
driven evolution. For diagnostic methods, it may be wise not to
use genes that code for antigens present in commercial vac-
cines. In addition, polymorphisms in the pertussis toxin pro-
moter region have also been described (15).
The region upstream of the outer membrane porin gene has
been used as a target for diagnostic PCR in only one previous
study (5). The assay described in that study had a sensitivity of
79% against culture when gel detection was used and a sensi-
tivity of 95% when DIG immunoblotting was used. In the
present study, new primers and probes were designed using the
outer membrane porin sequence data described by Li et al. (5).
A rapid-cycle protocol was designed; a carryover prevention
system (uracil-N-glycosylase) was included; probe detection
allowed differentiation among Bordetella spp.; an assay-specific
internal control was developed, allowing specimen preparation
to be minimal; and the assay was evaluated against a gold
standard method targeting a different gene. This method is the
first to fulfill the international consensus requirements for the
use of PCR in the detection of B. pertussis, as proposed by
Meade and Bollen (11) and outlined above. The assay does not
distinguish between B. parapertussis and B. bronchiseptica, but
this should only cause concern in interpreting results from
specimens obtained from immunocompromised patients, as B.
bronchiseptica is only rarely part of the normal flora of humans.
Nevertheless, interpretation of a positive B. parapertussis-B.
bronchiseptica POR result should be considered with caution.
The POR PCR assay allows a rapid, accurate, standardized,
and simplified approach to the laboratory diagnosis of pertussis.
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